newsfilter
← Earnings
Earnings Releases·

Aktis Oncology — Q3 2026 Earnings Summary

Aktis Oncology reported a net loss of $29.9 million for the third quarter ended September 30, 2026, while increasing its cash position to $492.9 million. The company initiated its third Phase 1b clinical trial, BActinium-2, to evaluate AKY-2519 in non-small cell lung cancer and other B7-H3 expressing tumors. Additionally, backfill cohorts were started in the ongoing NECTINIUM-2 and BActinium-1 trials to further assess safety and antitumor activity for AKY-1189 and AKY-2519. Aktis expects to present preliminary data for AKY-1189 in the first quarter of 2027 and for AKY-2519 later in 2027.

Company
AKTIS ONCOLOGY INC
Sector
Healthcare
Industry
Biotechnology